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Abstract: International guidelines recommend low-molecular-weight heparin (LMWH) as first-line
pharmacological option for the prevention of venous thromboembolism (VTE) in many patient
categories. Guidance on the optimal prophylactic dose is lacking. We conducted a systematic review
with meta-analysis and trial sequential analysis (TSA) of randomized controlled trials to assess
benefits and harms of low-dose LMWH versus placebo or no treatment for thrombosis prophylaxis
in patients at risk of VTE. PubMed, Cochrane Library, Web of Science, and Embase were searched
up to June 2019. Results were presented as relative risk (RR) with conventional and TSA-adjusted
confidence intervals (CI). Forty-four trials with a total of 22,579 participants were included. Six (14%)
had overall low risk of bias. Low-dose LMWH was not statistically significantly associated with
all-cause mortality (RR 0.99; 95%CI 0.85–1.14; TSA-adjusted CI 0.89–1.16) but did reduce symptomatic
VTE (RR 0.62; 95%CI 0.48–0.81; TSA-adjusted CI 0.44–0.89) and any VTE (RR 0.61; 95%CI 0.50–0.75;
TSA-adjusted CI 0.49–0.82). Analyses on major bleeding (RR 1.07; 95%CI 0.72–1.59), as well as serious
adverse events (SAE) and clinically relevant non-major bleeding were inconclusive. There was very
low to moderate-quality evidence that low-dose LMWH for thrombosis prophylaxis did not decrease
all-cause mortality but reduced the incidence of symptomatic and asymptomatic VTE, while the
analysis of the effects on bleeding and adverse events remained inconclusive.
Keywords: low-molecular-weight heparin; venous thromboembolism; meta-analysis
1. Introduction
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in hospitalized
and non-hospitalized patients [1]. The American Society of Hematology and American College
of Chest Physicians guidelines recommend low-molecular-weight heparin (LMWH) as a first-line
pharmacological option for most patients at risk of VTE [2,3]. Several prophylactic doses and types
of LMWH are used worldwide, which is reflected by differences in national summaries of product
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characteristics (SPCs) and dosing regimens of randomized controlled trials (RCTs). There is no
high-quality evidence or guidance on the optimal prophylactic LMWH dose. Preceding systematic
reviews on thrombosis prophylaxis have not specifically assessed benefits and harms associated with
different LMWH doses [4–10]. In addition, there have been very few direct comparisons of prophylactic
LMWH dose regimens, and therefore indirect evidence could provide a ‘second best’ estimate of
benefits and harms.
There is no generally accepted definition of different prophylactic LMWH dose categories, which
is why we previously categorized LMWH thrombosis prophylaxis regimens as either ‘low-dose’ or
‘intermediate-dose’, based on different registered doses in SPCs worldwide [11]. Using this approach
in a previous meta-analysis, we found that intermediate-dose LMWH, compared with placebo or no
treatment, was associated with a significant decrease in symptomatic VTE, at the cost of an increase in
major bleeding [11]. The main objective of the current study was to perform a systematic review with
meta-analysis and trial sequential analysis (TSA) comparing benefits and harms of low-dose LMWH
versus placebo or no treatment for thrombosis prophylaxis in all types of patients at risk of VTE [12].
2. Materials and Methods
We conducted this systematic review according to a pre-published protocol on PROSPERO (https:
//www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019124722) following the methodology
suggested by Jakobsen et al, the Cochrane Handbook for Systematic Reviews of Interventions,
the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement,




Studies were considered for inclusion irrespective of language, blinding, publication status, or
sample size. We included RCTs with adult patients allocated to receive thrombosis prophylaxis using
either low-dose LMWH, placebo, or no treatment, regardless of their underlying disease or whether
they were admitted to the hospital or visited the outpatient clinic.
2.1.2. Interventions
The experimental intervention was low-dose LMWH, irrespective of LMWH type or duration of
treatment. We a priori defined ‘low dose’ in our protocol according to the SPCs as approved by the
US Food and Drug Administration, the European Medicines Agency, and several national authorities
(Table 1). If different LMWHs or (weight-adjusted) doses were used in one trial, we classified the dose
according to what was used most frequently. We included trials evaluating ultra-low-molecular-weight
heparins and LMWHs not listed in Table 1 (e.g., LMWHs we were unable to classify into a specific
dose) in a sensitivity analysis. The control intervention was placebo or no treatment. Co-interventions
such as mechanical compression devices were allowed if they were applied in both treatment groups.
2.1.3. Outcomes
Predefined co-primary outcomes were all-cause mortality, symptomatic VTE, and major bleeding.
Secondary outcomes were serious adverse events (SAE), clinically relevant non-major bleeding, and
any VTE (including both symptomatic and asymptomatic events). All outcomes were assessed at
maximum follow-up. VTE was defined as deep vein thrombosis or pulmonary embolism, and the
diagnosis was accepted when objectified by an imaging technique or autopsy. We made no distinction
between distal or proximal, or lower versus upper extremity thrombosis. Major bleeding and clinically
relevant non-major bleeding were defined according to trial criteria. SAE were defined according to
the International Conference on Harmonisation of Good Clinical Practice definitions (ICH-GCP) [16].
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Table 1. LMWH dose definitions.
LMWH Type A Priori Defined as Low-Dose LMWH Dose Used in Included Trials
Bemiparin <3500 IU 2500 IU
Certoparin <5000 IU 3000 IU
Dalteparin <5000 IU 2500 IU a
Enoxaparin <40 mg 20 mg
Nadroparin <5700 IU 2850–3800 IU b,c
Parnaparin <4250 IU 3200 IU
Reviparin <3436 IU 1750 IU
Tinzaparin <4500 IU 3500 IU d
IU: International Units; LMWH: low-molecular-weight heparin; mg: milligrams; a Sandset et al. used weight-dependent
doses of 3000–5500 IU; b Fraisse et al. used weight-dependent doses of 3800–5700 IU; b Yoo et al. used weight-dependent
doses of 2850–5700 IU; c Xiao-Li et al. used weight-dependent doses of 41–62 IU/kg; d Sorensen et al. and Lassen et al.
used weight-dependent doses: 50 IU/kg.
2.2. Data Sources and Searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane
Library, PubMed/MEDLINE, EMBASE and Web of Science (Table S1). References of identified studies
were screened to identify further relevant trials. Finally, we searched the World Health Organization’s
International Clinical Trials Registry and ClinicalTrials.gov for ongoing trials (Table S2). The search
was last updated on 10 June 2019.
2.3. Data Extraction and Quality Assessment
Two authors (RJE, WB) independently identified trials for inclusion. Trials excluded on the basis
of full text were listed with reasons for exclusion. We extracted information on characteristics (year of
publication, country, numbers of sites and patients enrolled), participants (age, sex, eligibility criteria),
interventions (type, dose, and duration of LMWH treatment), and outcomes. We resolved differences
in opinion through discussion. Two authors (R.J.E., W.B.) independently assessed risks of bias of
the included trials according to the revised Cochrane risk of bias tool version 2 [17] in the following
five domains: “Bias arising from the randomization process”, “Bias due to deviations from intended
interventions”, “Bias due to missing outcome data”, “Bias in measurement of the outcome”, “Bias
in selection of the reported result”. RCTs were classified as ‘overall low risk of bias’ when all bias
domains were judged as ‘low risk’. Conversely, trials were classified as ‘overall high risk of bias’
when ‘some concerns’ or ‘high risk’ was judged in one or more domains [18]. Publication bias was
assessed by inspecting funnel plots for signs of asymmetry when 10 or more trials were included in the
analyses [12,14].
2.4. Data Synthesis and Analysis
We calculated relative risk (RR) with both conventional 95% confidence intervals (CIs) and
TSA-adjusted CI if there were two or more trials for each outcome.
2.4.1. Assessment of Significance
We used adjusted thresholds for statistical significance to correct for multiplicity issues due to
repeated testing. An alpha of 0.025 was used for the co-primary and secondary outcomes to keep the
family-wise error rate at a maximum of 5% [14]. In case of statistically significant RR, we calculated
numbers needed to treat (NNT) or numbers needed to harm (NNH) with 97.5% CI.
2.4.2. Meta-Analysis
Data were pooled using both a fixed-effect and a random-effects model. In case of discrepancy
between the models, we emphasized the most conservative estimate. Analyses were performed on an
intention-to-treat basis whenever possible or otherwise using an ‘available-case analysis’.
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2.4.3. Trial Sequential Analysis
Conventional meta-analyses may result in type-I errors due to risks of random error when few
data have been collected or due to repeated significance testing when a meta-analysis is updated with
new trials [19–23]. TSA is a sequential meta-analysis method that combines required information size
estimation (i.e., the number of patients needed to detect an a priori specified relative risk reduction) with
an adjusted threshold for statistical significance [21,22]. This adjusted threshold is more conservative
when data are sparse and becomes progressively more lenient as the accumulated sample size
approaches the required information size. Accordingly, the TSA-adjusted CI is initially wider than
the conventional 95% CI, but when the required information size has been reached, they become
identical. The required information size is calculated on the basis of the unweighted event proportion
in the control group, the assumption of a plausible relative risk reduction/increase (RRR/RRI), and the
anticipated heterogeneity variance (D2) of the meta-analysis. We applied TSA to all outcomes, using
the control event proportion from the actual meta-analyses; D2 as suggested by the meta-analysis;
alpha of 2.5%; beta of 90%; and an anticipated RRR/RRI of 20%.
2.4.4. Assessment of Heterogeneity
Statistical heterogeneity I2 was explored by the chi-squared test with significance set at a p-value
of 0.10. The quantity of heterogeneity was also measured by D2 [24]. Clinical heterogeneity was
explored by conducting explorative subgroup analyses.
2.4.5. Subgroup Analysis
We performed subgroup analyses according to overall risk of bias (low vs. high), type of patients,
LMWH type, duration of the intervention (less vs. more than 30 days), and length of follow-up (less vs.
more than 30 days). Statistically significant subgroup differences (test of interaction p < 0.05) provided
evidence of an intervention effect pending the subgroup.
2.4.6. Sensitivity Analysis
All analyses were re-conducted including trials that evaluated LMWH types not covered by
Table 1. In addition, sensitivity TSAs were conducted using an RRR as suggested by the overall
low-risk-of-bias studies and using a D2 of 25% if the actual D2 was 0%. In case of rare events (<2% in
the control group), TSA was also performed using Peto’s odds ratio.
SAE are often inconsistently reported and, in addition to assessing SAE according to trial
reporting, we estimated the number of patients with one or more SAE using two methods: (1) the
highest proportion of either reported mortality, symptomatic VTE, or major bleeding in each trial and
(2) all mortality, SAE, symptomatic VTE, and major bleeding events cumulated in each trial. The idea
is that the ‘true proportion’ of SAE should lie between these two extremes. Finally, to assess the impact
of attrition bias on the primary outcomes, we imputed missing outcome data in best-/worst-case and
worst-/best-case scenarios [14].
2.5. GRADE
We used GRADE to assess the quality of the body of evidence associated with each outcome [15].
3. Results
Our search strategy identified 10,374 records. After removal of duplicates and selections based on
titles and abstracts, 312 records remained. A total of 271 reports were excluded on the basis of full text,
and 41 records reporting 44 RCTs with a total of 22,579 patients were included (Figure 1).
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Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow-chart of 
study inclusion. 
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3.3.1. All-Cause Mortality 
Twenty-three trials with 15,487 patients reported data on all-cause mortality, including five trials 
with 4960 patients at overall low risk of bias. Mortality proportions were 8.0% in the LMWH group 
and 6.2% in the control group (Figure 2). Meta-analysis of low-risk-of-bias trials showed no 
statistically significant effect on all-cause mortality (RR 1.03; 95%CI 0.92 to 1.16; p = 0.60; I2 = 0%; TSA-
adjusted CI 0.88 to 1.20; Table 2). When assessing all trials, the conventional meta-analysis results 
remained similar, while TSA suggested futility, rejecting a 20% RRR or RRI in mortality. All 
sensitivity analyses were consistent with the primary analysis (Table 2, Table S7). Subgroup analyses 
showed no statistically significant tests of interaction (Table S8). The overall level of certainty of the 
evidence was low (Table 2). 
Figure 1. Preferred repo ting tems for systemati iews and meta-analyses (PRISMA) flow-chart of
study inclusion.
3.1. Characteristics of the Included Studies
Detailed characteristics of the 44 included trials are presented in Table S3. The year of publication
ranged from 1988 to 2018. Forty trials were in English, two in German, one in French, and one in
Chinese. Three trials were published as abstracts only, and the Chinese trial was assessed as abstract
only due to lacking translation capacity. There w re 24 single-center and 20 multicenter trials. Nine
different types of LMWH preparations were used, and several types of atients were evaluated:
orthopedic or immobilized patients (16 trials), surgical patients (13 trials), ambulatory cancer patients
(8 trials), acutely ill medical patients (4 trials), and neurological patients (3 trials).
3.2. Bias Risk Assessment
Six trials including 8172 patients were considered at overall low risk of bias (Table S4). Thirty-eight
trials were classified as overall high risk of bias. We did not suspect publication bias except for the
outcome any VTE, in which asymmetry in the funnel plot was observed (Figures S1–S4). Sensitivity
analyses of imputed missing data suggested potential for attrition bias in all primary outcomes, since
the imputed effect estimates in the best/worse and worse/best scenario’s suggested benefit and harm,
respectively (Table S5). Results of a post-hoc sensitivity analysis excluding trials published before 2005
were comparable to those of the main analyses (Table S6).
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3.3. Co-Primary Outcomes
3.3.1. All-Cause Mortality
Twenty-three trials with 15,487 patients reported data on all-cause mortality, including five trials
with 4960 patients at overall low risk of bias. Mortality proportions were 8.0% in the LMWH group
and 6.2% in the control group (Figure 2). Meta-analysis of low-risk-of-bias trials showed no statistically
significant effect on all-cause mortality (RR 1.03; 95%CI 0.92 to 1.16; p = 0.60; I2 = 0%; TSA-adjusted CI
0.88 to 1.20; Table 2). When assessing all trials, the conventional meta-analysis results remained similar,
while TSA suggested futility, rejecting a 20% RRR or RRI in mortality. All sensitivity analyses were
consistent with the primary analysis (Table 2, Table S7). Subgroup analyses showed no statistically
significant tests of interaction (Table S8). The overall level of certainty of the evidence was low (Table 2).J. Clin. Med. 2019, 8, 2039 7 of 17 
 
 
Figure 2. Forest plot of all-cause mortality. Forest plot of all-cause mortality at maximal follow-up of 
LMWH prophylaxis compared to placebo or no treatment, stratified according to population. The size 
of the squares reflects the weight of the trial in the pooled analysis. Horizontal bars represent 95% 
confidence intervals; LMWH, low-molecular-weight heparin; CI, confidence intervals. 
3.3.2. Symptomatic Venous Thromboembolism 
Twenty-five trials with 15,920 patients reported data on symptomatic VTE, including five trials 
with 4878 patients at overall low risk of bias. Symptomatic VTE proportions were 1.1% in the LMWH 
group and 1.8% in the control group (Figures 3 and 4). Meta-analysis of low-risk-of-bias trials showed 
a statistically significant beneficial effect on symptomatic VTE, which was not confirmed by TSA (RR 
0.65; 95%CI 0.45 to 0.94; p = 0.02; I2 = 0%; TSA-adjusted CI 0.15 to 3.05; Table 2). When including all 
trials, both conventional meta-analysis and TSA showed a beneficial intervention effect (RR 0.62; 
95%CI 0.48 to 0.81; p = 0.0006; I2 = 0%; TSA-adjusted CI 0.44 to 0.89; NNT 137; 97.5%CI 87 to 330; Table 
2; Figures 3 and 4). The primary analysis results were confirmed by three out of four sensitivity 
analyses (Table 2, Table S7). The direction of the intervention effect consistently suggested benefit in 
all subgroups, and there were no statistically significant tests of interaction (Table S8). The overall 
level of certainty of the evidence was moderate (Table 2). 
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Table 2. Conventional meta-analysis and trial sequential analysis outcomes.
Outcome Included Trials Trials (Patients) ConventionalMeta-Analysis a
Primary TSA a
α 2.5%; ß 90%; RRR 20%;
D2 Model Variance Based
Sensitivity TSA a
α 2.5%; ß 90%; RRR Based
on Low Risk Trials; D2
Model Variance Based
Sensitivity TSA a




Mortality Low bias risk 5 (4.960) RR 1.03 (0.92 to 1.16) RR 1.03 (0.88 to 1.20) Insufficient data (<5% of DIS) RR 1.03 (0.86 to 1.23) Low d, e, f
All 23 (15.487) RR 0.99 (0.85 to 1.14) RR 1.02 (0.89 to 1.16) b Insufficient data (<5% of DIS) RR 1.02 (0.90 to 1.15) Low d, g
Symptomatic VTE Low bias risk 5 (4.878) RR 0.65 (0.45 to 0.94) RR 0.67 (0.15 to 3.05) RR 0.67 (0.32 to 1.38) 0.67 (0.15 to 3.05) Moderate e
All 25 (15.920) RR 0.62 (0.48 to 0.81) RR 0.62 (0.44 to 0.89) c RR 0.62 (0.42 to 0.92) RR 0.62 (0.20 to 1.95) Moderate g
Major bleeding Low bias risk 5 (4.960) RR 1.70 (0.77 to 3.74) Insufficient data (<5% of DIS) Insufficient data (<5% of DIS) Insufficient data (<5% of DIS) Moderate f
All 33 (13.091) RR 1.07 (0.72 to 1.59) RR 1.01 (0.18 to 5.73) c RR 1.01 (0.52 to 1.93) RR 1.09 (0.75 to 1.60) Low e, f, g
SAE Low bias risk 1 (1.150) RR 0.89 (0.68 to 1.17) RR 0.89 (0.41 to 1.96) RR 0.89 (0.27 to 2.96) RR 0.89 (0.36 to 2.23) Low e, f, h
All 8 (5.180) RR 0.98 (0.78 to 1.25) RR 0.98 (0.37 to 2.58) Insufficient data (<5% of DIS) RR 0.98 (0.77 to 1.24) Very low d, e, f, g
Clinically relevant non-major
bleeding
Low bias risk 0 (0) - - - - -
All 5 (3.372) RR 1.50 (0.72 to 3.12) Insufficient data (<5% of DIS) Insufficient data (<5% of DIS) Insufficient data (<5% of DIS) Very low d, e, f, g
Any VTE Low bias risk 3 (1.254) RR 0.57 (0.38 to 0.84) RR 0.57 (0.11 to 2.82) RR 0.57 (0.32 to 1.01) Not performed (D2 >25%) Moderate e, i, k
All 30 (5.849) RR 0.61 (0.50 to 0.75) RR 0.63 (0.49 to 0.82) RR 0.63 (0.50 to 0.80) Not performed (D2 >25%) Low e, i, j, k
a Small discrepancies of the intervention effect estimates between traditional RevMan meta-analyses and the TSA-adjusted results may occur due to different pooling methods (for example
the inclusion of zero-event trials in TSA analyses); b TSA monitoring boundary for futility crossed; c sensitivity analysis using Peto’s odds ratio showed similar results; d downgraded for
inconsistency, since point estimates varied widely; e downgraded for imprecision, since TSA-adjusted confidence interval crossed ‘1’; f downgraded for imprecision, since conventional
confidence interval crossed ‘1’; g downgraded for risk of bias, since (some) included trials were at high risk of bias; h downgraded for indirectness, since only one trial was included under
assessment; i downgraded for risk of publication bias, since there was important asymmetry in the funnel plot; j downgraded for inconsistency, since point estimates varied widely and
there was moderate statistical heterogeneity; k upgraded, since there was a strong association. α: two-sided significance level, ß: power; D2: diversity; DIS: diversity-adjusted information
size; OR: odds ratio; RR: relative risk; RRR: relative risk reduction; SAE: serious adverse events; TSA: trial sequential analysis; VTE: venous thromboembolism.
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3.3.2. Symptomatic Venous Thromboembolism
Twenty-five trials with 15,920 patients reported data on symptomatic VTE, including five trials
with 4878 patients at overall low risk of bias. Symptomatic VTE proportions were 1.1% in the LMWH
group and 1.8% in the control group (Figures 3 and 4). Meta-analysis of low-risk-of-bias trials showed
a statistically significant beneficial effect on symptomatic VTE, which was not confirmed by TSA (RR
0.65; 95%CI 0.45 to 0.94; p = 0.02; I2 = 0%; TSA-adjusted CI 0.15 to 3.05; Table 2). When including
all trials, both conventional meta-analysis and TSA showed a beneficial intervention effect (RR 0.62;
95%CI 0.48 to 0.81; p = 0.0006; I2 = 0%; TSA-adjusted CI 0.44 to 0.89; NNT 137; 97.5%CI 87 to 330;
Table 2; Figures 3 and 4). The primary analysis results were confirmed by three out of four sensitivity
analyses (Table 2, Table S7). The direction of the intervention effect consistently suggested benefit in all
subgroups, and there were no statistically significant tests of interaction (Table S8). The overall level of
certainty of the evidence was moderate (Table 2).J. Clin. Med. 2019, 8, 2039 8 of 17 
 
 
Figure 3. Trial sequential analysis of symptomatic venous thromboembolism (VTE). Trial sequential 
analysis of symptomatic VTE at maximal follow-up of LMWH compared to placebo or no treatment. 
The required information size was calculated using α = 0.025, β = 0.90, relative risk reduction (RRR) = 
20%, diversity (D2) as suggested by trials, and a control event rate of 1.81%. The cumulative Z-curve 
was constructed using a random-effects model, and each cumulative Z-value was calculated after 
inclusion of a new trial (represented by black dots). The dotted horizontal lines represent the 
conventional naïve boundaries for benefit. The etched lines represent the trial sequential boundaries 
for benefit (positive), harm (negative), or futility (middle triangular area). The cumulative Z-curve 
crosses the TSA boundary for benefit, indicating future trials are very unlikely to change the 
conclusions. Note: the two most recent trials were excluded from this TSA because inclusion would 
result in an incorrect graphical display of the LanDeMets boundary for benefit. The TSA-adjusted 
confidence interval remained similar. 
Figure 3. Trial sequential analysis of symptomatic venous thromboembolism (VTE). Trial sequential
analysis of symptomatic VTE at maximal follow-up of LMWH compared to placebo or no treatment.
The required information size was calculated using α = 0.025, β = 0.90, relative risk reduction
(RRR) = 20%, diversity (D2) as suggested by trials, and a control event rate of 1.81%. The cumulative
Z-curve was constructed using a random-effects model, and each cumulative Z-value was calculated
after inclusion of a new trial (represented by black dots). The dotted horizontal lines represent the
conventional naïve boundaries for benefit. The etched lines represent the trial sequential boundaries for
benefit (positive), harm (negative), or futility (middle triangular area). The cumulative Z-curve crosses
the TSA boundary for benefit, indicating future trials are very unlikely to change the conclusions.
Note: the two most recent trials were excluded from this TSA because inclusion would result in an
incorrect graphical display of the LanDeMets boundary for benefit. The TSA-adjusted confidence
interval remained similar.
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Figure 4. Forest plot of symptomatic VTE. Forest plot of symptomatic VTE at maximal follow-up of
LMWH prophylaxis compared to placebo or no treatment, stratified according to patient type. The size
of the squares reflects the weight of the trial in the pooled analysis. Horizontal bars represent 95%
confidence intervals.
3.3.3. Major Bleeding
Thirty-three trials with 13,091 patients reported data on major bleeding, including five trials with
4960 patients at overall low risk of bias. Major bleeding proportions were 0.9% in the LMWH group and
0.8% in the control group (Figure 5). Meta-analysis of low-risk-of-bias trials showed a non-statistically
significant increase in major bleeding (RR 1.70; 95%CI 0.77 to 3.74; p = 0.19; I2 = 0%; Table 2). TSA could
not be conducted, since less than 5% of the required information size was accrued. When including
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all trials, both conventional meta-analysis and TSA showed no statistically significant effect (RR 1.07;
95%CI RR 0.72 to 1.59; p = 0.74; I 2= 0%; TSA-adjusted CI 0.18 to 5.73; Table 2). Sensitivity analyses were
consistent with the primary analyses (Table 2, Table S7). Subgroup analyses showed that low-dose
LMWH for more than 30 days was associated with higher risk of major bleeding as compared to shorter
treatments (RR 2.20; 95% CI 1.00 to 4.82 vs RR 0.84; 95%CI 0.53 to 1.32, p = 0.04 for test of interaction;
Table S8). The overall level of certainty of the evidence was low to moderate (Table 2).
3.4. Secondary Outcomes
3.4.1. Serious Adverse Events
Eight trials with 5180 patients reported data on SAE, although events were generally not defined
according to ICH-GCP. SAE proportions were 5.4% in the LMWH group and 3.8% in the control group
(Supplement Figure S5). The one trial at overall low risk of bias, including 1150 patients, showed no
statistically significant intervention effect on SAE (RR 0.89; 95%CI 0.68 to 1.17; p = 0.42; TSA-adjusted
CI 0.41 to 1.96; Table 2). This result was confirmed in both conventional meta-analysis and TSA of all
trials regardless of bias risk (RR 0.98; 95% CI 0.78 to 1.25; p = 0.89; I2 = 0%; TSA-adjusted CI 0.37 to 2.58;
Table 2). As predefined sensitivity analysis, we categorized mortality, symptomatic VTE, and major
bleeding events from 37 trials as SAE and used these data to estimate the proportion of patients with
one or more SAEs: the results were consistent with those of the primary analysis (Table S9). Subgroup
analyses showed no statistically significant tests of interaction. The overall level of certainty of the
evidence was very low to low (Table 2).
3.4.2. Clinically Relevant Non-Major Bleeding
Five trials with 3372 patients reported data on clinically relevant non-major bleeding. Clinically
relevant non-major bleeding proportions were 1.0% in the LMWH group and 0.7% in the control
group (Figure S6). No trials were at overall low risk of bias. Meta-analysis of all trials showed no
statistically significant intervention effect on clinically relevant non-major bleeding (RR 1.50; 95%CI 0.72
to 3.12; p = 0.28; I2 = 0%; Table 2), and TSA could not be conducted, since less than 5% of the required
information size was accrued. Sensitivity analyses were consistent with the primary analysis (Table 2,
Table S7). Subgroup analyses showed no statistically significant tests of interaction. The overall level
of certainty of the evidence was very low (Table 2).
3.4.3. Any Venous Thromboembolism
Thirty trials with 5849 patients reported data on any VTE, including three trials with 1254 patients
at overall low risk of bias. Proportions of any VTE were 10.7% in the LMWH group and 17.6%
in the control group (Figure S7). Meta-analysis of the low risk of bias trials showed a statistically
significant beneficial effect on any VTE, which was not confirmed by TSA (RR 0.57; 95%CI 0.38 to 0.84;
p = 0.005; I2 = 0%; TSA-adjusted CI 0.11 to 2.82; Table 2). When including all trials, both conventional
meta-analysis and TSA showed a beneficial intervention effect (RR 0.61; 95%CI 0.50 to 0.75; p < 0.00001;
I2 = 47%; TSA-adjusted CI 0.49 to 0.82; NNT 15; 97.5%CI 11 to 21; Table 2). The primary analysis
results were confirmed by all sensitivity analyses (Table 2, Table S7). Subgroup analyses showed no
statistically significant tests of interaction. The overall level of certainty of the evidence was low to
moderate (Table 2).
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4. Discussion
In this systematic review on low-dose LMWH versus placebo or no treatment, LMWH was not
associated with a statistically significant intervention effect on mortality, major bleeding, clinically
relevant non-major bleeding, or SAE. Conversely, we found a large beneficial intervention effect on both
symptomatic VTE and on any VTE which included asymptomatic events detected through screening.
These effects were consistent among subgroup and sensitivity analyses, but the effect size varied per
patient type, and the quality of the evidence was moderate. In the TSAs of mortality, symptomatic
VTE, and any VTE, the adjusted monitoring boundaries were crossed (respectively, for futility and
for benefit), indicating a low risk of random error. The intervention effects of low-dose LMWH on
SAE and bleeding events remain inconclusive, as TSA monitoring boundaries were not crossed, and
quality of evidence was low. There was a suggestion of publication bias in the reporting of any VTE,
and attrition bias may have influenced the primary outcomes.
4.1. Considerations on the Optimal Prophylactic Dose
Previous systematic reviews did not observe a mortality benefit for patients receiving LMWH
thrombosis prophylaxis compared to patients receiving placebo or no treatment, which is confirmed by
our results including TSA. Although it was previously thought that LMWHs might improve survival
in cancer patients, later systematic reviews found no survival benefit in cancer patients receiving
different prophylactic doses of LMWH [6,9]. Additionally, we detected no beneficial effect on mortality
in any patient category in a previous meta-analysis on intermediate-dose LMWH [11]. Nevertheless,
we cannot exclude the possibility of a smaller intervention effect than 20% RRR/RRI on mortality; this
would require many more randomized patients, as we used a 20% RRR for calculating the required
information size in TSA.
In line with previous literature, we found a consistent beneficial intervention effect on VTE in
subgroup analyses according to patient type, although effect sizes varied among subgroups. The overall
incidence of symptomatic VTE was low, resulting in an NNT of 137. Effect estimates were rather similar
regardless of bias risk (low risk RCTs estimated an RRR of 35%, while all RCTs combined estimated an
RRR of 41%), suggesting we may base our conclusions on the more accurate estimates derived from
the meta-analyses of all trials. Previous systematic reviews on thrombosis prophylaxis have found
larger relative risk reductions [6,7,10,25]. This could indicate that low-dose LMWH may be slightly
less effective for the prevention of VTE than more frequently used higher doses. However, this indirect
comparison should be viewed with caution, as differences between reviews regarding study selection
criteria could also explain the difference. A direct comparison in a homogeneous patient population is
required for strong inferences about the efficacy of low-dose LMWH compared to higher doses.
Finally, evidence on adverse events remains inconclusive. The point-estimate of the low-risk-of-bias
trials suggested a 70% RRI in major bleeding which was not statistically significant, while the estimate
including all trials was neutral. This difference may relate to bias risk but could also be explained by
trial characteristics: cancer and treatment duration are risk factors for major bleeding, and three out
of five low-risk-of-bias trials included oncological patients who were generally treated for a longer
duration [26]. The increased risk of major bleeding in the subgroup of oncological patients was
comparable to that reported in previous systematic reviews for this patient category [6,7]. Conversely,
the risk of major bleeding for other patient types was low compared to that indicated in other systematic
reviews [10,11,25]. This may be explained by the low LMWH dose but also by differences in included
patients or co-interventions. Data on clinically relevant non-major bleeding were reported by only
a few trials, and analyses were inconclusive. There was no apparent effect on SAE, confirmed by
sensitivity analyses in which we incorporated data from nearly all available trials. Assessment of these
two outcomes was hampered by wide variations in definitions and reporting between trials, resulting
in low- to very low quality evidence and limiting inferences on the harms of low-dose LMWH.
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4.2. Implications for Clinical Practice
In general, clinicians will not prescribe thrombosis prophylaxis without considering both
effectiveness and harms. This balance may differ depending on patients’ characteristics such as
disease type, severity of illness, or surgery. In prespecified subgroup analyses according to patient type,
we found that, in surgical patients, low-dose LMWH reduced both symptomatic and any VTE, without
evidence for increased major bleeding. In orthopedic patients, there was a statistically significant
reduction in any, but not in symptomatic, VTE, with no evidence for increased major bleeding events.
Although not statistically significant, there was a 39% RRR in symptomatic VTE, and the discrepancy
may be explained by low power. In oncological patients, a beneficial effect on symptomatic VTE, but
not on any VTE, was found. Additionally, the direction of the intervention effect suggested an increase
in major bleeding. There were no statistically significant beneficial or harmful effects in acutely ill
medical patients, suggesting either that there was a very small intervention effect with concurrent
high numbers needed to treat or that a low LMWH dose is insufficient for this type of patient. Recent
guidelines have recommended an individualized approach towards thrombosis prophylaxis in acutely
ill medical patients [2]. On the basis of our results, one could hypothesize that medical patients deemed
at high risk of VTE will mainly benefit from higher doses of thrombosis prophylaxis. Finally, only very
few neurological patients were included, limiting inferences for this subgroup.
This systematic review provides a general overview of the effects of low-dose LMWH: although
there are differences between patient subgroups, there also are many similarities in the direction
of effects. Overall, we found that low-dose LMWH was most effective in surgical, orthopedic, and
oncological patients, while the estimated RRI for bleeding events was low in most prespecified patient
subgroups, except for oncological patients. These results should be viewed in the perspective of the
limited quality of the evidence and the inherent limited power of subgroup analyses. In cases where
physicians are in doubt whether a patient should receive thrombosis prophylaxis or no prophylaxis
at all or when a higher prophylactic dose is deemed inappropriate with respect to bleeding risk,
clinicians may consider a low-dose LMWH for thrombosis prophylaxis, especially in surgical and
orthopedic patients.
4.3. Strengths and Limitations
Strengths of this review include its systematic and transparent methodology according to
recommendations by the Cochrane Handbook, the PRISMA statement, and the GRADE working
group. We used a prespecified protocol, a comprehensive search strategy without language restrictions,
although we did assess one Chinese article as abstract only, independent data extraction and bias
assessment by two authors, and incorporation of bias risk assessment in the results and conclusions.
Finally, we applied TSA to all outcomes to assess the risks of random error and to estimate the required
information size.
Nevertheless, several important limitations apply. Our main goal was to make general inferences
on the efficacy and safety of low-dose LMWH, using all available evidence. Consequently, there was a
high amount of clinical heterogeneity between trials. The balance between thrombosis and bleeding
may vary depending on patient subgroup characteristics: relying on overall effect estimates could
obscure more subtle associations or lead to wrong inferences about a subpopulation. However, the
distinction between different patient populations is somewhat arbitrary in any systematic review,
and we attempted to account for clinical heterogeneity by conducting several preplanned subgroup
analyses. This approach offers the benefit of increased power of the meta-analysis, and we found the
direction of the intervention effects was equal in most subgroups.
A second limitation concerns the inclusion of trials comparing low-dose LMWH to an inactive
comparator, which led to the selection of mainly older trials or trials assessing LMWH in specific
patient types or countries, limiting the generalizability of our results. In a post-hoc sensitivity analysis
excluding trials published before 2005, the results remained comparable, although no inferences could
be made for subgroups due to the very limited sample size.
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Third, to estimate the effect of low-dose LMWH on SAEs we conducted a sensitivity analysis
to estimate the proportion of patients having one or more SAEs. For this purpose, we categorized
mortality, symptomatic VTE, SAE, and major bleeding events from 37 trials as SAE. In reality, not all
symptomatic VTE and major bleeding events are SAEs by definition (i.e., a distal leg thrombosis may
be classified as adverse event, while pulmonary embolism can be a serious adverse event), but making
this distinction was impossible on the basis of insufficiently detailed trial reports. Last, the best-/worst-
and worst-/best-case analyses we performed to explore the influence of missing outcome data were
probably overpowered to detect potential attrition bias, since the incidence of lost to follow-up was
higher than the incidence of the primary outcomes.
5. Conclusions
In a wide variety of patients at risk of VTE, there was very low to moderate-quality evidence that
low-dose LMWH for thrombosis prophylaxis did not decrease all-cause mortality but reduced the
incidence of symptomatic and asymptomatic VTE, while results on the intervention effects on major
bleeding, clinically relevant non-major bleeding, and SAE remain inconclusive.
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